HK1183877A1 - 取代的吡啶化合物 - Google Patents

取代的吡啶化合物

Info

Publication number
HK1183877A1
HK1183877A1 HK13111517.6A HK13111517A HK1183877A1 HK 1183877 A1 HK1183877 A1 HK 1183877A1 HK 13111517 A HK13111517 A HK 13111517A HK 1183877 A1 HK1183877 A1 HK 1183877A1
Authority
HK
Hong Kong
Prior art keywords
substituted pyridine
pyridine compound
compound
substituted
pyridine
Prior art date
Application number
HK13111517.6A
Other languages
English (en)
Inventor
Tsuyoshi Nakamura
Hidenori Namiki
Naoki Terasaka
Akiko Shima
Masahiko Hagihara
Noriaki Iwase
Katsunori Takata
Osamu Kikuchi
Kazunari Tsuboike
Hiroyuki Setoguchi
Kenji Yoneda
Hidetoshi Sunamoto
Koji Ito
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of HK1183877A1 publication Critical patent/HK1183877A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
HK13111517.6A 2010-07-09 2013-10-11 取代的吡啶化合物 HK1183877A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010156590 2010-07-09
PCT/JP2011/065651 WO2012005343A1 (ja) 2010-07-09 2011-07-08 置換ピリジン化合物

Publications (1)

Publication Number Publication Date
HK1183877A1 true HK1183877A1 (zh) 2014-01-10

Family

ID=45441319

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13111517.6A HK1183877A1 (zh) 2010-07-09 2013-10-11 取代的吡啶化合物

Country Status (20)

Country Link
US (1) US9187450B2 (zh)
EP (1) EP2592076B1 (zh)
JP (1) JP5739426B2 (zh)
KR (1) KR101764458B1 (zh)
CN (1) CN103221405B (zh)
AU (1) AU2011274903B2 (zh)
BR (1) BR112013000389A2 (zh)
CA (1) CA2804924C (zh)
CO (1) CO6670582A2 (zh)
ES (1) ES2543176T3 (zh)
HK (1) HK1183877A1 (zh)
IL (1) IL223866A (zh)
MX (1) MX2013000359A (zh)
MY (1) MY158199A (zh)
NZ (1) NZ606100A (zh)
RU (1) RU2572606C2 (zh)
SG (1) SG186493A1 (zh)
TW (1) TWI506025B (zh)
WO (1) WO2012005343A1 (zh)
ZA (1) ZA201300155B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2860601C (en) * 2012-01-06 2016-07-05 Daiichi Sankyo Company, Limited Acid addition salt of substituted pyridine compound
JP2017019724A (ja) * 2013-10-25 2017-01-26 第一三共株式会社 置換ピリジン化合物および他の医薬の組み合わせ
LT3081566T (lt) * 2013-12-13 2018-05-25 Daiichi Sankyo Company, Limited 5-hidroksi-4-(trifluormetil)pirazolpiridino darinys

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
US6207671B1 (en) 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19741051A1 (de) * 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
MA24643A1 (fr) 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741399A1 (de) 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
WO1999041237A1 (en) 1998-02-13 1999-08-19 G.D. Searle & Co. Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
WO2000020402A1 (en) 1998-10-01 2000-04-13 Astrazeneca Ab Chemical compounds
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
RU2393151C2 (ru) * 2004-12-18 2010-06-27 Байер Шеринг Фарма Акциенгезельшафт 4-циклоалкилзамещенные производные тетрагидрохинолина и их применение в качестве лекарств
JP2008524137A (ja) 2004-12-18 2008-07-10 バイエル・ヘルスケア・アクチェンゲゼルシャフト （５ｓ）−３−［（ｓ）−フルオロ（４−トリフルオロメチルフェニル）メチル−５，６，７，８−テトラヒドロキノリン−５−オール誘導体およびｃｅｔｐ阻害剤としてのそれらの使用
CA2627722A1 (en) 2005-10-31 2007-06-21 Merck & Co., Inc. Cetp inhibitors
UY30118A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compueto amina trisustituido
KR101149274B1 (ko) 2006-07-20 2012-05-29 노파르티스 아게 Ｃετρ 억제제로서의 아미노-피페리딘 유도체
WO2008156715A1 (en) * 2007-06-20 2008-12-24 Merck & Co., Inc. Cetp inhibitors derived from benzoxazole arylamides
CA2707651A1 (en) 2007-12-03 2009-06-11 Novartis Ag 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
JP5291126B2 (ja) 2008-03-05 2013-09-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 三環式ピリジン誘導体、そのような化合物を含有する医薬、それらの使用及びそれらの調製方法

Also Published As

Publication number Publication date
SG186493A1 (en) 2013-01-30
CO6670582A2 (es) 2013-05-15
IL223866A (en) 2016-07-31
TW201206904A (en) 2012-02-16
EP2592076A1 (en) 2013-05-15
US9187450B2 (en) 2015-11-17
EP2592076B1 (en) 2015-05-13
KR20130093068A (ko) 2013-08-21
US20140213549A9 (en) 2014-07-31
EP2592076A4 (en) 2013-10-16
AU2011274903B2 (en) 2016-09-08
JPWO2012005343A1 (ja) 2013-09-05
CA2804924A1 (en) 2012-01-12
NZ606100A (en) 2014-08-29
CN103221405A (zh) 2013-07-24
WO2012005343A1 (ja) 2012-01-12
KR101764458B1 (ko) 2017-08-02
JP5739426B2 (ja) 2015-06-24
CN103221405B (zh) 2015-04-22
US20140005143A2 (en) 2014-01-02
ZA201300155B (en) 2013-09-25
ES2543176T3 (es) 2015-08-17
MX2013000359A (es) 2013-02-11
TWI506025B (zh) 2015-11-01
RU2572606C2 (ru) 2016-01-20
AU2011274903A1 (en) 2013-02-14
US20130109653A1 (en) 2013-05-02
RU2013105475A (ru) 2014-08-20
MY158199A (en) 2016-09-15
BR112013000389A2 (pt) 2016-06-07
CA2804924C (en) 2016-06-28

Similar Documents

Publication Publication Date Title
HRP20181788T1 (hr) Supstituirani spojevi piridinon-piridinil
AP3607A (en) Substituted imidazopyridazines
HK1171452A1 (zh) 取代的吡咯烷- -甲醯胺類
EP2590647A4 (en) PRO-NEUROGENIC COMPOUNDS
EP2605658A4 (en) SPIROXAZOLIDINONVERBINDUNGEN
HK1179964A1 (zh) 稠合的吡啶化合物
HK1188782A1 (zh) 取代的 -吡唑- -酚鈉
HK1188597A1 (zh) 連續芳環化合物
GB201002911D0 (en) Compound
GB201017315D0 (en) Compound
GB201007789D0 (en) Novel Compound
HK1183877A1 (zh) 取代的吡啶化合物
GB201007209D0 (en) Compound
GB201021228D0 (en) Compound
GB201015798D0 (en) Compound
GB201008820D0 (en) Compound
GB201005980D0 (en) Compound
GB201002810D0 (en) Novel compound
GB201003745D0 (en) Novel compounds ll

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190704